CompletedPhase 2

Bone Marrow Transplant in Treating Patients With Hematologic Cancers

United States125 participantsStarted 1993-03

Plain-language summary

RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying how well donor bone marrow transplant works in treating patients with hematologic cancers.

Who can participate

Age range

15 Years – 55 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of: * Acute myelogenous leukemia * Complete remission (CR) 1 - ALL except good cytogenetics defined as \[(inv16, t(8,21), t(15,17)\] * CR2 * Induction failures * Relapsed OR * Acute lymphocytic leukemia (ALL) * CR1 - high risk defined as overt CNS involvement, 1 or more risk factors (age 30 and over, WBC at least 20,000/mm\^3, at least 4 weeks to CR1, myeloid phenotype) * CR2 * Induction failures * Relapsed OR * Chronic myelogenous leukemia * Chronic phase (CP) 1 * Accelerated phase (AP)/CP2 OR * Chronic lymphocytic leukemia * At diagnosis - RAI stage III/IV or Binet C * Must undergo 1 induction regimen * Relapsed - any stage * Must have received no more than 3 regimens for diagnosis OR * Multiple myeloma * At diagnosis - stage II/III (primary refractory or sensitive) * Relapsed no more than 2 times - sensitive disease * Plasma cell leukemia OR * Myelodysplasia * All subtypes eligible OR * Myeloproliferative disorders * Poor response to medical therapy OR * Cytogenetic abnormalities * Must have a related donor who is genotypic 6 out of 6 HLA A, B, and DR match * Molecular DR matching required PATIENT CHARACTERISTICS: Age: * 15 to 55 Performance status: * Karnofsky 80-100% Life expectancy: * Not specified Hematopoietic: * See Disease Characteristics Hepatic: * Bilirubin no greater than 2.0 mg/dL…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Relapse-free survival

Timeframe: 5 years post transplant

Trial details

NCT IDNCT00005797

SponsorH. Lee Moffitt Cancer Center and Research Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2007-07

View on ClinicalTrials.gov More Chronic Myeloproliferative Disorders trials